Richard Law
Stock Analyst at Goldman Sachs
(2.64)
# 2,169
Out of 4,955 analysts
65
Total ratings
45.16%
Success rate
6.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $18.01 | +66.57% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $54.17 | +51.38% | 4 | Aug 6, 2025 | |
| ARQT Arcutis Biotherapeutics | Initiates: Neutral | $18 | $15.79 | +14.00% | 1 | Jul 25, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $5.54 | +224.91% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.44 | -44.85% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.73 | +248.53% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $22.02 | +40.78% | 3 | May 9, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $25.66 | +16.91% | 1 | Apr 8, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $14.61 | +64.33% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $66.65 | +9.53% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $4.50 | +144.44% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $16.01 | +193.57% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $52.82 | +19.27% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $42.52 | -12.98% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $10.13 | +650.62% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.73 | +412.82% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.30 | +735.62% | 4 | May 8, 2023 |
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $18.01
Upside: +66.57%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $54.17
Upside: +51.38%
Arcutis Biotherapeutics
Jul 25, 2025
Initiates: Neutral
Price Target: $18
Current: $15.79
Upside: +14.00%
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $5.54
Upside: +224.91%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.44
Upside: -44.85%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.73
Upside: +248.53%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $22.02
Upside: +40.78%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $25.66
Upside: +16.91%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $14.61
Upside: +64.33%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $66.65
Upside: +9.53%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.50
Upside: +144.44%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $16.01
Upside: +193.57%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $52.82
Upside: +19.27%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $42.52
Upside: -12.98%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $10.13
Upside: +650.62%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.73
Upside: +412.82%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.30
Upside: +735.62%